Leaders in the development of new marine-based biotechnology

The oceans cover 70% of the Earth's surface, and correspond to 90% of the biosphere. For millions of years, innumerable forms of marine life have evolved to produce an immense variety of chemical entities of exclusive sophistication. Among these, there are molecules with potent biological activities, developed as a form of biochemical warfare to survive in an extremely competitive environment.
 
PharmaMar has identified the antitumour potential of these molecules, and is actively developing them as innovative treatments for cancer.

Innovative Model
 
PharmaMar employs a comprehensive business model that includes all phases of drug development, from discovery to production to marketing.
 
This process starts with the discovery of new compounds of marine origin that can be used in the treatment of cancer; it continues in the commitment to research and develop these discoveries to deliver effective compounds to the marketplace. This drive to discover novel resources for, and to develop new approaches to, patient care provides PharmaMar with its basis for growth.
 
Small quantities of the samples are processed and analysed in our systems of biological models, specifically developed for the detection of antitumour activity. The fractionation of the samples using chromatological techniques allows the rapid isolation of molecules of interest and the elucidation without dilation of their chemical structure.
 
Next, the molecules with promising antitumour activity are subjected to pharmacological chemical programmes to establish a suitable production mechanism via chemical synthesis, thus avoiding the need to resort to the natural source.
 
With this approach, we continually discover new molecules equipped with exclusive mechanisms of action (MoA), which represents a great opportunity to advance in basic sciences and, more importantly, it opens potentially new channels for the treatment of cancer.